Advertisement
Advertisement
ELUT
Elutia Inc. Class A Common Stock
0.84
USDSponsored
+0.09
+11.52%
Nov 06, 15:59 UTC -5
Closed
After-Market
0.84
0.00
-0.05%
Elutia Inc. Class A Common Stock (ELUT) Earnings
ELUT Earnings Reports
Positive Surprise Ratio
ELUT beat 9 of 25 last estimates.
36%
Next Report
Date of Next Report
Mar 09, 2027
Estimate for Q4 26 (Revenue/ EPS)
$1.02M
/-$0.13
Implied change from Q3 26 (Revenue/ EPS)
-10.53%
/-7.14%
Implied change from Q4 25 (Revenue/ EPS)
-68.82%
/-108.78%
Elutia Inc. Class A Common Stock earnings per share and revenue
On Nov 05, 2026, ELUT reported earnings of -0.14 USD per share (EPS) for Q3 26, beating the estimate of -0.15 USD, resulting in a 8.50% surprise. Revenue reached 1.14 million, compared to an expected 1.02 million, with a 11.76% difference. The market reacted with a +11.52% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.13 USD, with revenue projected to reach 1.02 million USD, implying an decrease of -7.14% EPS, and decrease of -10.53% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
INmune Bio Inc. Common stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.17
Surprise
-13.64%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
FAQ
What were Elutia Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Elutia Inc. Class A Common Stock reported EPS of -$0.14, beating estimates by 8.5%, and revenue of $1.14M, 11.76% above expectations.
How did the market react to Elutia Inc. Class A Common Stock's Q3 2026 earnings?
The stock price moved up 11.52%, changed from $0.75 before the earnings release to $0.84 the day after.
When is Elutia Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Mar 09, 2027.
What are the forecasts for Elutia Inc. Class A Common Stock's next earnings report?
Based on --
analysts, Elutia Inc. Class A Common Stock is expected to report EPS of -$0.13 and revenue of $1.02M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.